Ardigen's news feed
October 1, 2020
Share news in:

Agnieszka Blum, PhD MD, joins Ardigen as the General Director of Immunology



Ardigen is proud to announce a new member joining its Board of Directors. Dr. Agnieszka Blum becomes the General Director of the Immunology Business Unit and brings her 10+ years of experience in immuno-oncology.  

Dr. Blum will open a new chapter for the Immunology Business Unit by adding broad knowledge and clinical expertise to the development of technological platforms moving cell therapies into the era of Artificial Intelligence.

Before joining Ardigen, dr. Blum held a number of significant technical, medical, and leadership roles. Dr. Blum coordinated the development of a GMP-grade clinical platform for the application of TCR-engineered T-cells with defined specificity in refractory AML, high-risk multiple myeloma and metastatic melanoma. During her time at Charité Universitätsmedizin Berlin, dr. Blum conducted and planned early phase clinical trials while coordinating the activities of multiple teams, including research, manufacturing, clinical, and pathology, within complex government-sponsored initiatives. She successfully implemented basic research ideas while managing complex grant applications, funding difficulties and avoided compromises in regard to product quality and trail monitoring. Recently, at the Mater Misericordiae University Hospital in Dublin, as Consultant Hematologist and NGS Laboratory Lead, dr. Blum implemented in clinical practice next generation sequencing diagnostics and treated cancer patients. 

Dr. Blum received her scientific degree from Humboldt University in Berlin, working on the GMP-grade technology for the induction and expansion of low frequency/ naive  CD8 positive T-cells, where she also completed her medical training jointly with Jagiellonian University Collegium Medicum in Cracow.

Sept. 23, 2020
Ardigen has received funding to accelerate its AI-driven TCR discovery platform for novel cell therapies
August 26, 2020
AI aided design of epitope-based vaccine for the induction of cellular immune responses against SARS-CoV-2
Go up